Iotalamic acid
Appearance
(Redirected from Conray)
Clinical data | |
---|---|
Trade names | Conray, Glofil-125, Cysto-Conray II, others |
Other names | MI-216, iothalamate meglumine, Iothalamic acid (USAN US) |
AHFS/Drugs.com | Consumer Drug Information |
License data |
|
Routes of administration | Intravascular[1] |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.017.181 |
Chemical and physical data | |
Formula | C11H9I3N2O4 |
Molar mass | 613.916 g·mol−1 |
3D model (JSmol) | |
| |
|
Iotalamic acid, sold under the brand name Conray, is an iodine-containing radiocontrast agent. It is available in form of its salts, sodium iotalamate and meglumine iotalamate. It can be given intravenously or intravesically (into the urinary bladder).[1]
A radioactive formulation is also available as sodium iothalamate I-125 injection (brand name Glofil-125). It is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of people with kidney disease.[2]
References
[edit]- ^ a b c "Conray- iothalamate meglumine injection". DailyMed. 1 January 2021. Retrieved 23 February 2022.
- ^ a b "Glofil-125- sodium iothalamate i-125 injection injection, solution". DailyMed. 9 December 2019. Retrieved 23 February 2022.
- ^ "Cysto-Conray II- iothalamate meglumine injection". DailyMed. 31 December 2020. Retrieved 23 February 2022.
External links
[edit]- "Iothalamate meglumine". Drug Information Portal. U.S. National Library of Medicine.
- "Iothalamate sodium". Drug Information Portal. U.S. National Library of Medicine.